BFGP 385

Drug Profile

BFGP 385

Alternative Names: BF 385; BF/GP 385; GP 385

Latest Information Update: 27 Feb 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scherer Healthcare
  • Developer Ono Pharmaceutical; Scherer Healthcare
  • Class Antihypertensives; Antiplatelets; Heart failure therapies
  • Mechanism of Action Cyclic GMP phosphodiesterase inhibitors; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Heart failure; Hypertension; Nephritis; Peripheral vascular disorders; Thrombosis

Most Recent Events

  • 27 Feb 2001 No-Development-Reported for Nephritis in USA (Unknown route)
  • 26 Feb 2001 No-Development-Reported for Heart failure in USA (Unknown route)
  • 26 Feb 2001 No-Development-Reported for Hypertension in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top